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Abstract
Introduction: Heart failure is a frequent complication after acute myocardial infarction (MI) and carries a poor prognosis. Current
treatments inhibit the renin-angiotensin-aldosterone system but suppression of aldosterone may be incomplete. The aldosterone
antagonist spironolactone has been shown to improve survival in patients with chronic, severe heart failure. Eplerenone is a selective
aldosterone antagonist expected to have a lower incidence of hormonal side effects than spironolactone.
Aims: To assess the evidence on the therapeutic value of eplerenone for treatment of heart failure in adults.
Evidence review: The evidence base consists of one large double-blind placebo-controlled multicenter randomized trial in over 6000
patients with postmyocardial infarction (MI) heart failure, comparing eplerenone plus standard therapy with placebo plus standard
therapy. All the main outcomes were patient-oriented. Evidence from this trial shows that eplerenone improves survival and reduces
cardiovascular hospitalization/mortality, compared with standard treatment alone. The incidence of hormonal side effects is no greater
than with placebo. The risk of hyperkalemia is significantly increased, especially in patients with low creatinine clearance. Eplerenone
was both more effective and more costly than standard treatment alone. The cost-effectiveness ratio has been estimated at
$US10 402–21 876 per life-year gained.
Place in therapy: Eplerenone reduces mortality compared with current treatment alone in patients with post-MI heart failure, at
additional cost. Direct comparative evidence is needed to assess its efficacy versus spironolactone. It may be valuable in patients who
are intolerant to the hormonal side effects of spironolactone. 
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Core evidence place in therapy summary for eplerenone as an addition to standard therapy in
adult patients with heart failure after myocardial infarction
Outcome measure Evidence Implications
Patient-oriented evidence
Decrease in all-cause mortality Clear Improved survival with add-on eplerenone compared with standard therapy alone
Decrease in combined cardiovascular mortality/hospitalization Clear Lower risk with add-on eplerenone compared with standard therapy alone
Decrease in cardiovascular mortality Substantial Lower risk with add-on eplerenone compared with standard therapy alone
Decrease in sudden cardiac death Substantial Lower risk with add-on eplerenone compared with standard therapy alone
Decrease in combined all-cause mortality/hospitalization Substantial Lower risk with add-on eplerenone compared with standard therapy alone
Decrease in cardiovascular hospitalization Substantial No significant difference between add-on eplerenone and standard therapy alone
Incidence of hormonal side effects Substantial No greater incidence with eplerenone than with placebo
Reduction in length of stay Limited Shorter length of stay with add-on eplerenone compared with standard therapy
alone in patients hospitalized for heart failure
Improvement in quality of life Limited No significant difference in utility score between eplerenone and standard therapy
alone at 12 months
Reduction of symptom burden No evidence
Prevention of progression to poor functional status No evidence
continued overleaf…Scope, aims, and objectives
Eplerenone (Inspra®, Pfizer) is a selective aldosterone antagonist
first developed for the treatment of hypertension and approved by
the US Food and Drug Administration (FDA) in October 2003 for
the treatment of adults with heart failure occurring after a
myocardial infarction (MI).
Eplerenone has higher selectivity for aldosterone
(mineralocorticoid) receptors and lower affinity for androgen and
progesterone receptors compared with the existing aldosterone
antagonist, spironolactone. As a result, eplerenone should
provide effective aldosterone blockade with a lower incidence of
hormonal side effects than spironolactone, which should lead to
improved tolerability.
This article reviews the evidence base for the clinical use of
eplerenone in adult patients with post-MI heart failure. Use of
eplerenone in children or in other conditions, such as hypertension,
is outside the scope of this review.
Methods
English-language literature searches were conducted on March
2–4, 2005 in the following databases, searching from the
beginning of the database to date unless otherwise stated. The
search strategy was “(eplerenone OR Inspra) AND (heart AND
failure)” unless otherwise stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date. Search strategy “(eplerenone OR Inspra) AND (heart
AND failure OR CHF),” which was expanded by Automatic
Term Mapping to “((‘eplerenone’[Substance Name] OR
eplerenone[Text Word]) OR (‘eplerenone’[Substance Name] OR
Inspra[Text Word])) AND ((‘heart’[MeSH Terms] OR heart[Text
Word]) AND failure[All Fields] OR (‘congestive heart failure’[Text
Word] OR ‘heart failure, congestive’[MeSH Terms] OR
CHF[Text Word])) AND English[Lang]”
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
strategy: “((eplerenone OR Inspra) AND (heart AND failure OR
CHF)) AND LG=EN AND HUMAN=YES”
• Database of Abstracts of Reviews of Effectiveness (DARE),
NHS Economic Evaluations Database (NHSEED), Health
Technology Assessment (HTA),
www.york.ac.uk/inst/crd/darehp.htm. All three databases were
searched together. All fields searched
• NHS HTA, www.ncchta.org. Search strategy “eplerenone OR
Inspra”
• National Guideline Clearing House, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk. Search strategy “eplerenone OR Inspra”
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm. Entire site searched. Search
strategy “eplerenone OR Inspra”
• Clinical Evidence (BMJ), www.clinicalevidence.com. Search
strategy “eplerenone OR Inspra”
• www.clinicaltrials.gov. Search strategy “eplerenone OR Inspra”
• www.clinicalstudyresults.org. Search strategy “eplerenone OR
Inspra”
After removal of duplicates, a total of 279 records were
identified. Records were manually reviewed and 275 were
excluded for the following reasons: nonsystematic reviews
(n=170), animal studies (n=11), studies in other diseases (n=24),
studies in children (n=1), letters, editorials, news items,
comments and corrections (n=42), conference reviews (n=5),
articles about other drugs or treatments (n=19), and articles not
investigating the clinical use of eplerenone in heart failure (n=3).
One clinical trial, one economic evaluation, and two articles
describing their design rationale remained and were included in
the evidence base (Table 1).
Online abstracts from the following congresses were searched
using the search strategy “eplerenone” unless otherwise stated:
• American Heart Association, all conferences from 2001 to
2003, http://aha.agora.com/abstractviewer/search.asp
• European Society of Cardiology 2003 held August 30 to
September 3, 2003, Vienna, Austria.
http://www.escardio.org/knowledge/congresses/abstracts/
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…table continued
Outcome measure Evidence Implications
Disease-oriented evidence
Incidence of hyperkalemia Clear  Eplerenone is associated with an increased risk of hyperkalemia, especially in patients
with creatinine clearance <50 mL/min
Serum potassium and creatinine clearance should be carefully monitored throughout
eplerenone therapy and prompt dose adjustment made if required
Economic evidence
Cost effectiveness  Clear Addition of eplerenone is more costly and more effective than standard therapy alone,
$US10 402–21 876 per life-year gained127
• European Society of Cardiology Heart Failure Update held
June 12–15, 2004, Wroclaw, Poland.
http://www.escardio.org/knowledge/congresses/abstracts/ 
• European Society of Cardiology 2004 held August 28 to
September 1 2004, Munich, Germany.
http://www.escardio.org/knowledge/congresses/abstracts/
Nineteen abstracts were identified and available online, of which
15 were excluded because they were animal studies (n=14) or did
not investigate the clinical effect of eplerenone (n=1), and four
were included (Table 1).
Meeting abstracts from 2002 or later were identified by searching
BIOSIS Previews, http://www.datastarweb.com, 1996 to date,
using the search strategy “(eplerenone OR Inspra) AND (heart
AND failure OR CHF) AND PT=MEETING$ AND LG=EN AND
(YEAR=2002 OR YEAR=2003 OR YEAR=2004 OR YEAR=2005).”
A total of 20 abstracts were retrieved, of which three were
duplicates of abstracts already identified from the online
abstracts of the congresses listed above, leaving 17
nonduplicates. Of these, 14 were excluded for the following
reasons: animal studies (n=8), studies in other diseases (n=3),
review (1), duplicate publications of data presented in full papers
(2), and the remaining 3 were included. One additional abstract
was identified from the reference list of a review paper and
included (Table 1).
The searches were updated on July 21–25, 2005. A total of 70
new records were identified, of which all 70 were excluded for the
following reasons: animal studies (n=2); studies on other drugs
(n=3); letters, notes, and editorials (n=5); articles that did not
investigate the clinical use of eplerenone (n=1); and
nonsystematic reviews (n=59). The manufacturer, Pfizer, provided
one additional full paper (Ravis et al. 2005) which replaced an
earlier abstract (Ravis et al. 2004), a further full paper (Pitt et al. in
press), and a presentation with corrected data (Gheorghiade et al.
2004b) which replaced an earlier abstract (Gheorghiade et al.
2004a) (Table 1).
Disease overview
Heart failure is a complex clinical syndrome (Hunt et al. 2001;
Remme & Swedberg 2001). The most common form is chronic
heart failure; acute heart failure is sometimes used to mean acute
pulmonary edema or cardiogenic shock, but the use of the term
is discouraged (Remme & Swedberg 2001). The European Society
for Cardiology Task Force on Heart Failure considered that no
definition of chronic heart failure is entirely satisfactory, but
proposed the following: “heart failure is a pathophysiological state
in which an abnormality of cardiac function is responsible for the
failure of the heart to pump blood at a rate commensurate with
the requirements of the metabolizing tissues” (Remme &
Swedberg 2001). 
There is no objective definition of heart failure, and diagnosis
relies on clinical judgment (Remme & Swedberg 2001). The
American College of Cardiology/American Heart Association
(ACC/AHA) Task Force considered the key symptoms of heart
failure to be dyspnea and fatigue (which may result in impaired
exercise tolerance) and fluid retention (which may lead to
pulmonary and/or peripheral edema) (Hunt et al. 2001). The
severity of heart failure is most commonly assessed using the
New York Heart Association (NYHA) functional classification (Hunt
et al. 2001): 
• class I, patients have symptoms of heart failure only at
exertion levels that would limit normal individuals
• class II, patients have symptoms of heart failure on ordinary
exertion
• class III, patients have symptoms of heart failure on less than
ordinary exertion
• class IV, patients have symptoms of heart failure at rest. 
In addition, the ACC/AHA Task Force has proposed a
complementary classification that considers heart failure as a
progressive disease (Table 2); patients are expected to progress
from one stage to the next unless progression is slowed or
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Number of records
Category Full papers Abstracts
Initial search 279 36
records excluded 275 29
records included 4 7a
Additional papers identified 01
Search update, new records 69 1
records excluded 69 1
records included 0 0
Publications not available on
databases and supplied by
manufacturer
21
b
Level 1 clinical evidence (systematic
review, meta analysis)
00
Level 2 clinical evidence (RCT) 3
c 7
Level ≥3 clinical evidence 00
trials other than RCT
case reports
Economic evidence 1 1
Total records included 68
aOne of these abstracts later replaced by presentation with corrected data supplied by
manufacturer, and one replaced by a full paper.
bPresentation.
cPlus 2 describing design and rationale.
For definitions of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 
 stopped by medical treatment (Hunt et al. 2001). The NYHA
functional classification relates primarily to patients in stages C
and D of the ACC/AHA classification (Hunt et al. 2001).
Heart failure can result from any cardiac disorder that impairs the
ability of the ventricle to fill with or eject blood, but the most
common underlying cause is coronary artery (or heart) disease
(Hunt et al. 2001). It includes acute MI, other acute ischemic
coronary disease, angina pectoris, atherosclerotic cardiovascular
disease, and all other forms of heart disease (AHA 2004). This
review is concerned with heart failure occurring as a
complication after MI.
Burden of disease
The British Heart Foundation (BHF) estimates that the incidence
rate for MI in the UK is approximately 600 per 100 000 men aged
30–69 years and approximately 200 per 100 000 women of the
same age (BHF 2005). The prevalence of MI (i.e. the number of
people who have had an MI and survived) in the UK is estimated
at approximately 4% of men and 2% of women (BHF 2005). In the
USA, the prevalence of MI was estimated at 5% in men and 2.3%
in women in 2002 (AHA 2004). Mortality data collected and
published by the World Health Organization (WHO) show
considerable international variations, with higher rates of MI
mortality in Northern Europe than in Southern Europe and low MI
mortality in Japan (Table 3) (WHO 2005).
Around half of people experiencing an MI die within 28 days
(case fatality rate) in the UK (BHF 2005). Comparison of a
population survey in Oxfordshire in 1994–1995 with a previous
survey in the same region in 1966–1967 showed that case fatality
had significantly (P<0.05) improved over the period by 28% in
men and 32% in women (Volmink et al. 1998). Data from the
National Registry of Myocardial Infarction show a similar
improving trend in the USA; in-hospital mortality after MI
declined from 11.2% to 9.4% (P=0.0001) between 1990 and
1999 (Rogers et al. 2000).
Heart failure is a common complication following MI (Cleland et al.
2005). The VALIANT registry of over 5000 MI patients in nine
countries in 1999–2001 (part of the VALIANT [VALsartan in acute
myocardial INfarcTion] clinical trial) found that 42% of patients had
heart failure and/or left ventricular systolic dysfunction during
hospitalization (Velazquez et al. 2004). Data from over 60 000 MI
patients enrolled in four trials of fibrinolytic therapy showed that
29% had mild-to-moderate heart failure (Hasdai et al. 2003). The
AHA estimates that within 6 years after a recognized MI, 22% of
men and 46% of women will be disabled by heart failure (AHA 2004). 
The prevalence of heart failure and the number of hospital
admissions for the disease is increasing in Europe and the USA
(Haldeman et al. 1999; Szucs 2000; Stewart et al. 2002). This
partly reflects the increasing average age of the population in
most Western countries, as heart failure becomes increasingly
common with advancing age (Remme & Swedberg 2001). It
may also reflect the increased success of treatment for acute
MI, such as thrombolytic therapy, as more patients survive the
initial event and thus remain alive and at potential risk of
developing complications (Szucs 2000). Improved management
strategies for heart failure, resulting in improved survival, also
tend to increase the number of patients living with the condition
(Szucs 2000).
Patients who develop heart failure after MI have a worse
prognosis than patients who do not. In the VALIANT registry, the
in-hospital mortality rate was 13% in MI patients with heart failure
and/or left ventricular systolic dysfunction during hospitalization,
compared with 2.3% in patients without (P<0.001) (Velazquez et
al. 2004). After adjustment for baseline risk factors, patients with
heart failure and/or left ventricular systolic dysfunction were over
four times more likely to die before discharge than patients
without (hazard ratio 4.12, 95% confidence interval 3.08, 5.56)
(Velazquez et al. 2004). Mild-to-moderate heart failure after MI is
also associated with increased mortality; 30-day mortality was
8% for patients with mild-to-moderate heart failure, compared
with 2% for patients without (Hasdai et al. 2003). 
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Stage Description
A Patients at high risk of developing heart failure but
with no identified structural abnormalities and no
symptoms
B Patients with structural abnormalities but no symptoms
of heart failure
C Patients with symptoms of heart failure associated with
structural abnormalities
D Patients with advanced structural abnormalities and
marked symptoms of heart failure at rest
Table 2 | American College of Cardiology/American Heart
Association (ACC/AHA) Task Force classification 
of heart failure stages (adapted from Hunt 
et al. 2001)
Country Yeara Mortality rate per 100 000 population, acute
myocardial infarction
Men Women
France 2000 51.1 35.5
Italy 2001 72.8 49
Japan 2002 40.7 32
Spain 2001 72.6 48.4
Sweden 2001 145.4 110.5
UK 2002 104.9 80.7
USA 2000 72.7 64.6
aMost recent year in the online database.
Table 3 | Mortality from acute myocardial infarction [adapted
from World Health Organization (WHO) 2005]
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Even if systolic function is preserved the mortality risk remains
elevated; a study of 3166 MI patients in Denmark reported 1-year
mortality rates of 6% for patients without heart failure, 22% for
patients with heart failure and preserved systolic function, and 35%
for patients with heart failure and systolic dysfunction (P<0.0001)
(Møller et al. 2003). In the US National Registry of Myocardial
Infarction, patients presenting with heart failure as a complication of
ST-elevation MI were at higher risk for in-hospital death than patients
without heart failure (21.4% compared with 7.2%, P<0.0005) (Wu et
al. 2002). In a population survey of 1915 patients with MI in
Minnesota, median survival after the development of heart failure
was 4 years, with a worse outcome in patients with impaired left
ventricular ejection fraction (Hellermann et al. 2005). When patients
with all acute coronary syndromes (not just MI) were considered,
patients with heart failure on admission to hospital had higher
mortality in hospital (12% compared with 2.9%, P<0.0001) and at 6
months after discharge (8.5% compared with 2.8%, P<0.0001) than
patients without heart failure (Steg et al. 2004). Health-related quality
of life, measured with the Nottingham Health Profile, was impaired in
a sample of elderly patients with heart failure compared with a
healthy reference population matched for age and sex (Cline et al.
1999). In patients with post-MI heart failure, poorer health status as
measured by the Kansas City Cardiomyopathy Questionnaire
(KCCQ) was associated with higher 1-year risk of cardiovascular
mortality or hospitalization (Soto et al. 2004).
As well as elevated mortality risk, patients with heart failure after
MI are also less likely to return to paid work than patients with MI
but without heart failure. In a small population survey of 89 patients
with MI in the Midwestern USA, 33% of patients who did not return
to work had heart failure, compared with only 3% of patients who
did return to paid work (P<0.001) (McBurney et al. 2004). 
The economic burden of heart failure is substantial. It has been
estimated that treating heart failure accounts for 1–2% of the
total healthcare budget in France, The Netherlands, and the UK
(Cleland 1998; Stewart et al. 2002). In the USA, the total
inpatient and outpatient cost for heart failure in 1991 was
estimated at $US38.1 billion, 5.4% of the total healthcare
budget (Hunt et al. 2001). The total direct cost of heart failure to
the UK National Health Service (NHS) has been estimated at
£716 million in 1995 (Stewart et al. 2002). The largest
component of cost (69%) was hospital treatment, and the cost
of prescribed medications was estimated at 18%. The large
proportion attributable to hospital costs appears to be
consistent across other European countries, including Sweden
and Switzerland (Szucs 2000). In addition to these costs,
Stewart et al. (2002) also estimated that a further £751 million
was incurred in the UK for long-term nursing home care and
hospitalizations with a secondary diagnosis of heart failure. 
Certain subgroups of patients account for a disproportionately
large percentage of costs. Clearly, since hospitalization is the
major cost component, patients who require hospital treatment
comprise such a subgroup (Szucs 2000). It has also been
estimated that patients with more severe heart failure (NYHA class
III or IV) consume over 90% of the total medical costs of heart
failure (Szucs 2000).
No cost or economic data were identified relating specifically to
patients with heart failure as a post-MI complication, as opposed
to patients with heart failure from other causes. However, a study
based on a decision-analysis model applied to eight European
countries found that the follow-up costs for the first year after MI
(excluding the acute costs of treating the initial event) ranged from
€2050 per patient in Portugal to €8631 per patient in Austria (Levy
et al. 2003). In the USA, the cost of MI after the acute treatment
phase has been estimated at $US1678 per patient per year in
patients with diabetes mellitus (O’Brien et al. 2003), and
$US19 840 per patient over 10 years in patients undergoing
cardiac catheterization (Eisenstein et al. 2001). 
Pathophysiology
The pathophysiology underlying the symptoms of heart failure is
not fully understood (Remme & Swedberg 2001), and symptom
severity does not necessarily relate to the degree of cardiac
function (Hunt et al. 2001). The development of heart failure is
considered to be a progressive process, characterized by
structural changes in the heart and especially in the left ventricle,
resulting in an increase in ventricular wall thickness (Hunt et al.
2001). This process is referred to as left ventricular hypertrophy or
cardiac remodeling, and may be an important contributor to the
development and worsening of symptoms (Hunt et al. 2001).
However, there are diverse mechanisms for heart failure
progression, and the exact role of remodeling is not fully
understood.
Heart failure can be considered as an inappropriate response of
the systems that normally regulate blood pressure and blood
volume, of which the renin-angiotensin-aldosterone system is a
particularly important component (Fig. 1). 
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Fig. 1 | The renin-angiotensin-aldosterone system and the
pathophysiology of heart failure. ACE, angiotensin-converting
enzymeInjury to the heart (e.g. from MI) reduces cardiac output (the volume
of blood pumped per minute), which in turn reduces the flow of
blood around the body and tends to reduce arterial blood pressure.
Reduced blood flow to the kidneys stimulates the release of renin,
an enzyme which converts angiotensinogen to angiotensin I. A
second enzyme, angiotensin-converting enzyme (ACE), found
mainly in the lungs, converts angiotensin I to angiotensin II.
Angiotensin II has numerous actions on the cardiovascular system
(Remme 1999). It increases sympathetic nerve activity, which in turn
increases heart rate and tends to increase cardiac output.
Sympathetic stimulation can also increase renin release. Angiotensin
II also acts as a peripheral vasoconstrictor, causing blood vessels to
narrow and thus tending to increase arterial blood pressure, and
stimulates release of aldosterone from the adrenal cortex. 
Aldosterone is a steroid hormone (sometimes referred to as a
mineralocorticoid, because its main effects are on mineral
balance) that acts on the kidney tubule to increase reabsorption
of salt and water and indirectly increases potassium excretion.
The increase in salt and water retention increases blood volume,
which tends to increase both cardiac output and blood pressure.
In healthy individuals and acute situations, restoration of cardiac
output and blood pressure to normal inhibits renin release and
switches off the renin-angiotensin-aldosterone system. However,
renin-angiotensin-aldosterone production also occurs locally in
tissues such as the heart, blood vessels, and kidneys, and these
local systems may become progressively and chronically
activated (Remme 1999). Chronic activation of the renin-
angiotensin-aldosterone system is maladaptive and may
contribute to the characteristic symptoms of heart failure. Fluid
retention results in peripheral and pulmonary edema, and
pulmonary edema may give rise to breathlessness.
Vasoconstriction limits the blood flow to muscles and may
contribute to impaired exercise tolerance. Fluid retention and
increased blood pressure increase the strain on the heart, which
in turn tends to promote cardiac remodeling as the ventricular
muscle mass increases to meet the increased load. Angiotensin II
also has direct effects on cardiac remodeling (Remme 1999). 
There is evidence that aldosterone may also contribute directly to
cardiac remodeling and damage to other organs. Aldosterone-
generating enzymes and aldosterone receptors have been
identified in heart muscle and blood vessels, indicating that these
tissues can synthesize and respond to aldosterone independently
of the adrenal gland (Pitt et al. 2003c).
In animal models, aldosterone in combination with a high-salt diet
is associated with increased oxidative stress, inflammation of
coronary blood vessels, cardiac hypertrophy, cardiac fibrosis and
necrosis, renal vascular damage, and proteinuria (Rocha & Funder
2002; Rudolph et al. 2004; Shieh et al. 2004). These effects could
contribute to the development of cardiac remodeling,
nephrosclerosis, and stroke (Rocha & Funder 2002). Aldosterone-
induced cardiac fibrosis increases the stiffness of the ventricle,
which may contribute to the development of ventricular
dysfunction and heart failure (Struthers 2002), and in clinical
studies plasma aldosterone concentrations have been correlated
with left ventricular hypertrophy, vascular stiffness, and mortality
(Rudolph et al. 2004). Aldosterone has also been shown to
increase tissue levels of ACE, endothelin, and norepinephrine
(noradrenaline) (Pitt et al. 2003c). In the blood vessels, aldosterone
has been shown to inhibit fibrinolysis and to reduce endothelial
nitric oxide (which in turn reduces the ability of the blood vessels
to relax in response to vasodilator agents), and may mediate tissue
injury by a variety of mechanisms (Struthers 2002). Aldosterone
may also block the reuptake of norepinephrine and other
catecholamines in the heart, thus potentiating the effect of
sympathetic nervous system stimulation and possibly contributing
to the development of cardiac arrhythmias and sudden cardiac
death (Struthers 2002). Aldosterone can also decrease the
sensitivity of pressure receptors in animals and humans, and this
may also be linked to arrhythmias (Struthers 2004).
Current therapy options
Treatment guidelines have been published for the management of
patients with heart failure in the USA (Hunt et al. 2001) and Europe
(Remme & Swedberg 2001; Swedberg et al. 2005). US guidelines
for the management of ST-elevation MI (Antman et al. 2004) also
refer to the treatment of heart failure as a post-MI complication.
The main classes of drugs used in heart failure treatment are ACE
inhibitors, angiotensin II receptor antagonists, diuretics, digoxin,
spironolactone, beta blockers, and hydralazine/isosorbide
dinitrate (ICSI 2004) (Table 4). The recent update to the European
guidelines (Swedberg et al. 2005) recommends aldosterone
receptor antagonists in addition to ACE inhibitors, beta blockers
and diuretics.
According to the European guidelines (Swedberg et al. 2005), the
aims of treatment for heart failure include: 
• prevention of disease development and progression
• improved or maintained health-related quality of life
• improved survival.
There is broad agreement between the drugs recommended in
the US guidelines and European guidelines for heart failure (Hunt
et al. 2001; Remme & Swedberg 2001; Swedberg et al. 2005). The
US guidelines recommend a combination of four classes of drugs
(ACE inhibitors, beta blockers, diuretics, and digitalis) for routine
management of patients with symptomatic left ventricular
dysfunction, based on evidence and/or generally agreed
effectiveness (Hunt et al. 2001). In addition, the guidelines also
recommend the following drugs as being probably
useful/effective but with a lower level of evidence in support:
• spironolactone in patients with class IV heart failure symptoms,
preserved renal function and normal serum potassium
• angiotensin II receptor antagonists instead of ACE inhibitors in
patients receiving digitalis, diuretics, and beta blockers and
who cannot be given an ACE inhibitor because of cough or
angioedema
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• hydralazine and a nitrate in patients receiving digitalis,
diuretics, and beta blockers and who cannot be given an ACE
inhibitor because of hypotension or renal insufficiency.
The recent European guidelines provide broadly similar
recommendations, though they recommend aldosterone
antagonists in addition to ACE inhibitors, beta blockers, and
diuretics in patients with NYHA class III–IV heart failure and in
patients with post-MI heart failure with left ventricular systolic
dysfunction and signs of heart failure or diabetes (Swedberg 
et al. 2005).
The guidelines for treatment of ST-elevation MI are consistent with
those for heart failure. They recommend early use of beta
blockers and long-term treatment with an ACE inhibitor (or an
angiotensin II receptor antagonist in patients who cannot tolerate
ACE inhibitors) in patients recovering from MI (Antman et al.
2004). Aldosterone receptor antagonists are also recommended
in patients who are already receiving an ACE inhibitor, who have
a left ventricular ejection fraction of ≤40% and symptomatic heart
failure or diabetes, and who do not have significant renal
dysfunction or elevated serum potassium (Antman et al. 2004). 
Unmet needs
Despite the availability of numerous treatments and the publication
of practice guidelines for their use, there is still room for
improvement in the management of heart failure. Hospital
admissions due to heart failure increased in the USA between 1985
and 1995 according to data from the National Hospital Discharge
Survey (Haldeman et al. 1999), and current treatment guidelines
consider that mortality due to the disease is increasing (Hunt et al.
2001; Remme & Swedberg 2001). The VALIANT registry study
found that treatment of patients with heart failure and/or left
ventricular systolic dysfunction as a post-MI complication often
failed to meet guideline recommendations (Velazquez et al. 2004).
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Drug class Subsets of patients Characteristics
Systolic dysfunction
ACE inhibitors NYHA class I–IV Slow disease progression
Improve exercise capacity
Reduce hospitalizations and mortality
May induce cough and/or rash
Contraindicated if serum potassium >5.5 mmol/L, in pregnancy, in
patients with severe renal artery stenosis and patients with
symptomatic hypotension
Angiotensin II receptor antagonists NYHA class I–IV Improve cardiac output
Preferred alternative in patients with ACE inhibitor-induced cough,
unless high serum potassium and/or renal dysfunction is present
Hydralazine/isosorbide dinitrate Patients intolerant to ACE inhibitors In patients with ACE inhibitor-induced cough an angiotensin II receptor
antagonist is preferred because of greater ease of use
Alternative to ACE inhibitors if serum potassium is elevated
Diuretics Patients with fluid overload Diuretics should not be sole therapy
Monitor for fluid and electrolyte balance, including potassium,
magnesium, blood urea nitrogen, and creatinine
Spironolactone NYHA class III–IV May induce hormonal side effects, e.g. painful gynecomastia in men
Digoxin NYHA class II–IV, patients with atrial
fibrillation, left ventricular dilatation, high
filling pressure
Improves symptoms, exercise tolerance, and quality of life
No effect on mortality
Requires monitoring of serum levels due to potential toxicity
Beta blockers Stable NYHA class I–IV Reduce mortality and hospitalization
Improve exercise tolerance
May take several months for beneficial effects to develop
May produce bradycardia and/or atrioventricular block
Diastolic dysfunction
ACE inhibitors NYHA class I–IV May cause serious hypotension; use with caution
Diuretics Patients with fluid retention May cause orthostatic hypotension; use with caution
Beta blockers Patients with atrial fibrillation Requires higher dose than in systolic dysfunction
ACE, angiotensin-converting enzyme; ICSI, Institute for Clinical Systems Improvement; NYHA, New York Heart Association.
Table 4 | Current pharmacologic treatments in heart failure [adapted from Institute for Clinical Systems Improvement (ICSI) 2004]
 One problem may relate to the phenomenon of “aldosterone
escape.” Although ACE inhibitor treatment produces an acute
reduction in serum aldosterone levels, the level of aldosterone
rises again in long-term therapy and may return to baseline in
some patients (Struthers 2004). Aldosterone escape has been
linked to increased risk of cardiovascular events and reduced
exercise capacity, and has been suggested as a possible
mechanism for the blunting of the beneficial effects of ACE
inhibitors over time (Struthers 2004). The mechanism of
aldosterone escape is unclear, but may be related to non-ACE-
dependent pathways for synthesis of angiotensin II (e.g.
chymase), and/or direct synthesis of aldosterone in tissues such
as the brain, heart, and blood vessels (Struthers 2004).
Recognition of aldosterone escape has resulted in increased
interest in aldosterone antagonists, since these agents directly
block the action of aldosterone. Pivotal in this research was the
Randomized Aldactone Evaluation Study (RALES) (Pitt et al.
1999). This study randomized 1663 patients with chronic severe
heart failure and a left ventricular ejection fraction of ≤35% to
double-blind treatment with either the aldosterone antagonist
spironolactone (25 mg/day) or placebo, in addition to standard
treatment with ACE inhibitors, loop diuretics, and (in most cases)
digoxin. It was terminated early after an interim analysis revealed
that addition of spironolactone reduced all-cause mortality by
30%, reduced hospitalization for worsening heart failure by 35%,
and improved NYHA functional classification, compared with
standard treatment alone (all P<0.001) (Pitt et al. 1999).
However, spironolactone is not without drawbacks. It has
affinity for androgen and progesterone receptors as well as
aldosterone (mineralocorticoid) receptors, so it can be
associated with troublesome hormonal side effects such as
gynecomastia, breast pain and impotence in men and
abnormal vaginal bleeding in women. In RALES, gynecomastia
or breast pain occurred in 10% of men treated with
spironolactone, compared with 1% of placebo-treated men
(P<0.001), causing 10 men in the spironolactone group to
discontinue treatment (Pitt et al. 1999). Furthermore, because
one of the effects of aldosterone is to increase potassium
excretion, suppression of the renin-angiotensin-aldosterone
system by ACE inhibitors, angiotensin II receptor antagonists,
or aldosterone antagonists tends to promote potassium
retention. Impaired renal function may also promote potassium
retention, as the ability of the kidney to excrete excess
potassium is reduced, and mild-to-moderate renal
insufficiency is common in patients with advanced heart
failure, especially in patients with concomitant conditions such
as diabetes (Sica et al. 2003). The combination of drug therapy
and impaired renal function means that hyperkalemia is not
uncommon in patients with heart failure, and may be a serious
complication as it can increase the risk of cardiac arrhythmias
and sudden cardiac death (Sica et al. 2003). Strategies for
minimizing hyperkalemia include restriction of dietary
potassium intake, and dose reduction or temporary withdrawal
of drugs that suppress the renin-angiotensin-aldosterone
system. Aldosterone receptor antagonist treatment is at
greatest risk of inducing hyperkalemia in patients with
moderate renal impairment and serum potassium of
≥4.5 mmol/L (Sica et al. 2003). In patients with more advanced
renal failure, the risk of hyperkalemia has limited the use of
aldosterone antagonists (McLaughlin et al. 2004). However, in
patients with end-stage renal disease (ESRD) the effects of
aldosterone blockade on potassium excretion should be
minimal, since there is little or no renal excretion to be
affected. Limited evidence from a small number of patients
indicates that the risk of hyperkalemia with aldosterone
antagonists may indeed be lower in ESRD patients, although
further studies are required (McLaughlin et al. 2004). A recent
pharmacokinetic study reported that after single or multiple
dosing with 100 mg/day eplerenone, approximately 10% of the
administered dose was removed by hemodialysis (Ravis et al.
2005). This study also concluded that no dose adjustment of
eplerenone is necessary in patients with renal dysfunction
(Ravis et al. 2005).
The ideal treatment for heart failure would therefore have an
effect on some or all of the following outcomes compared with
current treatment: reduction in mortality; reduction in
cardiovascular morbidity; improvement in symptoms, functional
status and/or health-related quality of life; attenuation of heart
failure progression; reduction in the need for hospitalization;
reduction in overall costs and/or demonstrated cost
effectiveness; improved patient tolerability (e.g. low incidence of
side effects that lead to discontinuation of therapy); and low risk
of hyperkalemia.
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Outcome
All-cause mortality Combined cardiovascular mortality/hospitalizationa
Lower with eplerenone (P=0.008) Lower with eplerenone (P=0.002)
Relative risk 0.85 (95% CI 0.75, 0.96) Relative risk 0.87 (95% CI 0.79, 0.95)
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy included ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers (75%),
and coronary reperfusion therapy (45%).
aHospitalization was defined as a nonfatal event causing or prolonging hospitalization.
CI, confidence interval.
Table 5 | Effects of eplerenone on all-cause mortality and combined cardiovascular mortality/hospitalization (adapted from Pitt et al.
2003b; level 2 evidence)133
Clinical evidence with eplerenone
The evidence base for the use of eplerenone in post-MI heart
failure currently consists of one large double-blind randomized
controlled trial (RCT), the Eplerenone Postacute myocardial
infarction Heart Failure Efficacy and SUrvival Study (EPHESUS)
(Pitt et al. 2001; Pitt et al. 2003b). This study was conducted in
over 6000 patients with a mean follow-up of 16 months. The
primary outcomes were all-cause mortality and a combined
endpoint of cardiovascular death or hospitalization for
cardiovascular causes (heart failure, MI, stroke, or ventricular
arrhythmia). Both of these are clearly patient-oriented
outcomes. The secondary efficacy outcomes (all-cause
hospitalization/mortality, cardiovascular mortality, and
cardiovascular hospitalizations) provide further patient-oriented
evidence. Data on symptoms, functional status, and health-
related quality of life were also collected during the study
(Spertus et al. 2002), though as yet these results have not been
published. Disease-oriented outcomes included the incidence
of hyperkalemia (Pitt et al. 2003b). The study was also designed
to investigate additional disease-oriented outcomes including
cardiac remodeling, heart rate variability, neurohormonal
profile, collagen metabolism, thrombolytic balance, vascular
compliance, and proteinuria (Pitt et al. 2001), although as yet
the results for these outcome measures have not been
published as full papers.
All-cause mortality
All-cause mortality was one of the two primary endpoints in
EPHESUS, and the study was powered to have a chance of
88.3% of detecting a reduction in all-cause mortality of 18.5% for
eplerenone compared with placebo at a significance level of 0.04
(Pitt et al. 2001). EPHESUS reported clear evidence that addition
of eplerenone to standard therapy produced a significant
reduction in all-cause mortality, compared with placebo plus
standard therapy (Table 5). Standard therapy in EPHESUS
consisted of optimal medical treatment for MI as selected by the
investigators. At baseline, ACE inhibitors or angiotensin II
receptor antagonists were used in 87% of patients, beta blockers
in 75%, aspirin in 88%, and diuretics in 60%. In addition, 45% of
patients received reperfusion therapy or revascularization (Pitt et
al. 2003b). This pattern of treatment is broadly in line with that
recommended in treatment guidelines for post-MI patients and
patients with heart failure (see Current therapy options section),
and indicates that the survival benefit conferred by adding
eplerenone represents a therapeutic gain over the survival benefit
that can be achieved with current treatment. The dose of
eplerenone chosen, 25 mg/day for 4 weeks then titrated up to a
maximum of 50 mg/day, was lower than that required for
significant hemodynamic and/or diuretic effects (Pitt et al. 2001),
and suggests that the survival benefit was due to direct effects of
aldosterone blockade rather than to effects on blood volume or
pressure (see Disease overview section).
A further analysis showed that the survival benefit of eplerenone
was apparent at 30 days after randomization (Pitt et al. in press).
Combined cardiovascular hospitalization/mortality
EPHESUS provided clear evidence that addition of eplerenone to
standard therapy also reduced the combined risk of death or
hospitalization from cardiovascular causes (Table 5), which was
the other of the two primary endpoints in the study. 
Combined all-cause hospitalization/mortality
Eplerenone significantly reduced the risk of hospitalization or
death from any cause, compared with standard treatment alone
(Table 6). This was a secondary endpoint in the EPHESUS trial.
Cardiovascular mortality
EPHESUS showed that eplerenone reduced the risk of death
from cardiovascular causes by 17% compared with standard
therapy alone (Table 6). Eplerenone also significantly reduced
the risk of sudden cardiac death. There was no statistically
significant reduction in the risk of death from acute MI, heart
failure, stroke, or other cardiovascular causes with eplerenone
(Table 6).
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Outcome
All-cause mortality/
hospitalizationa
Cardiovascular mortality due to:
Any cause Sudden cardiac death AMI Heart
failure
Stroke Other
Lower with eplerenone (P=0.02)
Relative risk 0.92 (95% CI 0.86,
0.98)
Lower with eplerenone (P=0.005)
Relative risk 0.83 (95% CI 0.72,
0.94)
Lower with eplerenone (P=0.03)
Relative risk 0.79 (95% CI 0.64,
0.97)
NSD NSD NSD NSD
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy included ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers (75%),
and coronary reperfusion therapy (45%).
aHospitalization was defined as a nonfatal event causing or prolonging hospitalization.
AMI, acute myocardial infarction; CI, confidence interval; NSD, not statistically significantly different.
Table 6 | Effects of eplerenone on combined all-cause mortality/hospitalization and cardiovascular mortality (adapted from Pitt et al.
2003b; level 2 evidence)All-cause hospitalization
Addition of eplerenone did not reduce the risk of all-cause
hospitalization, compared with standard treatment alone (Table 7).
When the number of episodes of all-cause hospitalization was
assessed (rather than the number of patients hospitalized), there
was also no statistically significant difference between the
treatment groups (P=0.12) (Pitt et al. 2003b). 
Cardiovascular hospitalization
Eplerenone reduced the risk of hospitalization for heart failure,
compared with standard therapy alone, but showed no
statistically significant difference for the risk of hospitalization for
acute MI, stroke, ventricular arrhythmia, or any cardiovascular
cause (Table 7). When the data were analyzed in terms of number
of episodes of hospitalization a similar pattern was seen, except
that the difference in the number of episodes of hospitalization for
any cardiovascular event also reached statistical significance
(P=0.03) (Pitt et al. 2003b).
Tolerability
There was no statistically significant difference between the
EPHESUS treatment groups in the percentage of patients with
adverse events, and the number who discontinued due to
adverse events was also similar (Table 8). Eplerenone was also no
more likely than placebo to be associated with hormonal adverse
effects such as gynecomastia and impotence in men or breast
pain in women (Table 8). This contrasts with the result for
spironolactone in RALES, where 10% of men reported
gynecomastia or breast pain (Pitt et al. 1999).
Hyperkalemia
Clear evidence from the main analysis of EPHESUS and a post-
hoc analysis showed that eplerenone was associated with a
significantly higher incidence of hyperkalemia (defined as serum
potassium >5.5 mmol/L) and serious hyperkalemia (defined as
serum potassium ≥6 mmol/L) (Table 9). More patients in the
eplerenone group had to be hospitalized for treatment of
hyperkalemia, compared with the group receiving standard
therapy alone (Table 9). However, only one death in the placebo
group and none in the eplerenone group was attributed to
hyperkalemia. The post-hoc analysis of EPHESUS investigated
“worst-case assumptions” in which any sudden deaths or deaths
of unknown cause were included in the analysis of deaths
possibly linked to hyperkalemia, and found that eplerenone was
still associated with significantly lower mortality than standard
therapy alone (Table 9). These data suggest that eplerenone-
induced hyperkalemia was nonfatal and that the survival benefit
with eplerenone outweighed any risk due to hyperkalemia, at least
under the conditions of a clinical trial.
Length of stay
A retrospective analysis examined the length of hospital stay in
EPHESUS patients who were hospitalized for heart failure (n=828)
(Gheorghiade et al. 2004b). The mean length of stay per
hospitalization episode was significantly shorter in eplerenone-
treated patients than in patients receiving standard treatment
alone (9.2 days compared with 10.8 days, P=0.012). The total
number of days hospitalized for heart failure was also significantly
lower in the eplerenone group than the standard treatment alone
group (13.3 days compared with 16.9 days, P=0.0009)
(Gheorghiade et al. 2004b).
Osteopontin 
A group of 476 patients in EPHESUS were randomized to a
substudy investigating the prognostic value of various laboratory
parameters at baseline (Ketelslegers et al. 2004a). This study
found that patients who died during the study had significantly
(P<0.05) higher baseline levels of aldosterone, cortisol, renin,
vasopressin, natriuretic peptides, interleukin-6, osteopontin, C-
reactive protein, and type I collagen, compared with patients who
survived (Ketelslegers et al. 2004a). A further analysis examined
the effect of eplerenone on serum osteopontin (a cytokine
associated with inflammation) in 193 patients receiving standard
therapy alone and 195 patients receiving eplerenone (Ketelslegers
et al. 2004b). At baseline, there was no significant difference
between the groups in serum osteopontin. However, after 9
months the mean osteopontin level in the eplerenone group was
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Outcome
All-cause hospitalizationa Hospitalization due to:
Any cardiovascular cause AMI Heart failure Stroke Ventricular
arrhythmia
NSD NSD NSD Lower with eplerenone (P=0.03)
Relative risk 0.85 (95% CI 0.74, 0.99)
NSD NSD
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy included ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers (75%),
and coronary reperfusion therapy (45%).
aHospitalization was defined as a nonfatal event causing or prolonging hospitalization.
AMI, acute myocardial infarction; CI, confidence interval; NSD, not statistically significantly different.
Table 7 | Effects of eplerenone on all-cause and cardiovascular hospitalization (adapted from Pitt et al. 2003b; level 2 evidence)
 significantly lower than that in the placebo group (376.2 ng/mL
compared with 423.9 ng/mL, P<0.01) (Ketelslegers et al. 2004b).
However, the clinical significance of this finding is unclear.
Health status and health-related quality of life
Utility assesses the relative value of the patient’s health state on a
scale where 0=dead and 1=perfect health. Negative utility scores
are possible, as some health states may be considered worse
than death. Utility scores were obtained from a subgroup of 1123
patients from English-speaking countries at 12 months into the
EPHESUS trial, using the EuroQoL(EQ)-5D instrument (Weintraub
et al. 2005). The mean utility score was slightly higher in the
eplerenone group than in the group receiving standard therapy
alone at 12 months (0.802 compared with 0.779), but the
difference was not statistically significant (Weintraub et al. 2005).
Other measures of health status, functional impairment and health-
related quality of life were included in the design of EPHESUS
(Spertus et al. 2002). Results have been published showing that
the overall score at 4 weeks on the Kansas City Cardiomyopathy
Questionnaire, a disease-specific health status measure,
correlated significantly (P<0.001) with 1-year cardiovascular
mortality or hospitalization in a cohort of 1516 patients from the
study (Soto et al. 2004). However, no results have yet been
published comparing health status in eplerenone-treated patients
with that in patients receiving standard therapy only.
Economic evidence
EPHESUS included an economic analysis, and this provided
good evidence that addition of eplerenone to standard
treatment was both more effective and more costly than
standard treatment alone. Data on healthcare resource use
(hospitalization, outpatient procedures, and drugs) were
collected prospectively during the trial, and combined with unit
costs for the USA (Weintraub et al. 2005) or The Netherlands
(Zhang & Weintraub 2004) to estimate total direct healthcare
costs during the trial period. The US analysis has been fully
published (Weintraub et al. 2005), while the analysis using Dutch
costs has been published only in abstract form (Zhang &
Weintraub 2004). 
For the US analysis, an investigator who was blind to treatment
group assigned all hospitalizations to a Medicare Diagnosis-
Related Group (DRG) and coded outpatient procedures
according to the current Medicare fee schedule. Costs for these
items were estimated based on 2001 Medicare fees and
reimbursement rates. All medications were costed using the US
average wholesale price for 2001, except eplerenone which was
assigned its average wholesale price for 2004, and all
medications were assumed to continue for the duration of
follow-up for each patient. The eplerenone cost was $US3.60
per patient per day. Costs were calculated for the average
duration of follow-up (16 months). Life-years lost for those
patients who died during the trial period were estimated using
survival data from three different epidemiologic studies: the
Framingham Heart Study, Saskatchewan Health database, and
the Worcester Heart Attack Registry. Patients who survived
during the trial period were considered to have 0 life-years lost.
The difference between life-years lost in the eplerenone and
placebo groups gave the number of life-years gained with
eplerenone. Lifetime cost-effectiveness ratios ($US per life-year
gained) were estimated from the number of life-years gained
and the projected lifetime costs. Costs beyond the EPHESUS
trial period were estimated by projecting forward the costs in
years 2 and 3 of the trial. All costs and life-years were
discounted by 3% per year.
As discussed earlier, utility scores were obtained from a subgroup
of 1123 patients from English-speaking countries at 12 months
into the trial, using the EQ-5D questionnaire. The number of life-
years lost was multiplied by the mean utility score in each
treatment group to estimate the number of quality-adjusted life-
years (QALYs) lost. As the utility scores were derived only from a
subgroup of patients this was considered to be a sensitivity
analysis, with the estimate of cost per life-year gained being the
main analysis (Weintraub et al. 2005).
The Dutch analysis appeared to use similar methods, except that
the discount rate was 4% per year, costs for eplerenone were not
presented, and only the Framingham Heart Study and
Saskatchewan Health database were used to estimate life-years
gained (Zhang & Weintraub 2004). However, the information
available in the abstract is limited.
Outcome
Discontinuations due to AEs (number of patients) Any AE Gynecomastia in men  Impotence in men Breast pain in women
Placebo 149
Eplerenone 147a
Placebo 79.5%
Eplerenone 78.9%
NSD
Placebo 0.6%
Eplerenone 0.5%
NSD
Placebo 0.9%
Eplerenone 0.9%
NSD
Placebo 0.3%
Eplerenone 0.1%
NSD
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy could include ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers
(75%), and coronary reperfusion therapy (45%).
aNo between-group comparison reported.
AE, adverse event; NSD, not statistically significantly different.
Table 8 | Tolerability of eplerenone (adapted from Pitt et al. 2003b; level 2 evidence)
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eplerenone was $US1513 per patient over the trial period. This
was the only component of cost that was statistically significantly
different between the eplerenone group and the group receiving
standard treatment only, although there were numerical
differences in hospital costs that partly offset the additional costs
of eplerenone (Table 10). Fewer life-years were lost in the
eplerenone group, as expected from the survival benefit
demonstrated in the clinical study analysis (see Clinical evidence
section). The mean number of life-years gained by addition of
eplerenone was 0.1 (Framingham), 0.06 (Saskatchewan), and 0.13
(Worcester) (Weintraub et al. 2005). Thus, addition of eplerenone
to standard therapy was both more effective and more costly than
standard therapy alone. The cost-effectiveness ratio was
$US13 718 per life-year gained (Framingham estimate),
$US21 876 (Saskatchewan estimate), or $US10 402 (Worcester
estimate) (Weintraub et al. 2005). There was no significant
difference between the treatment groups in utility scores, and the
cost per QALY gained was $US20 579 (Framingham estimate),
$US32 405 (Saskatchewan estimate), or $US15 330 (Worcester
estimate) (Weintraub et al. 2005). Whether these cost-
effectiveness ratios represent acceptable use of resources
depends on circumstances and policies in different healthcare
systems and/or institutions and is a matter for the judgment of
individual decision makers. The authors of the US economic
analysis (Weintraub et al. 2005) argue that these cost-
effectiveness ratios for eplerenone compare favorably with those
for other interventions and with a “threshold” of $US50 000 per
life-year gained (see Resource utilization section).
The analysis with Dutch costs (Zhang & Weintraub 2004) produced
a similar pattern, with numerically smaller hospital costs in the
eplerenone group but no statistically significant difference (Table
10). However, this abstract did not present estimates of the cost of
eplerenone, overall costs, or cost-effectiveness ratios.
No data that would allow an estimate of indirect costs were
collected during EPHESUS (Weintraub et al. 2005). However, as
the mean age of the EPHESUS patients was 64 years, it is likely
that some would have already retired from employment and thus
indirect costs may be quite small. Direct evidence is needed to
assess this possibility.
Resource utilization
The evidence base for eplerenone (the EPHESUS study) relates to
the use of eplerenone as an additional treatment on top of existing
management strategies for post-MI heart failure. There is no
evidence indicating that eplerenone could replace any of the other
therapies. Thus, the acquisition cost of eplerenone would be a net
addition to the drug budget for the duration of therapy. In the
USA, the average wholesale price of eplerenone is $US112.50 per
patient per month (Barnes & Howard 2005), which equates to
approximately $US1350 per patient per year. The optimal duration
of therapy with eplerenone is uncertain, but a period of 1–2 years
has been suggested (Pitt 2003).
Hospitalization is the main component of cost in the management
of heart failure (see Disease overview section). As the addition of
eplerenone to standard therapy reduces the risk of cardiovascular
hospitalization compared with standard therapy alone, it might be
expected that the reduction in hospitalization costs could offset
part or all of the additional costs of eplerenone. However,
economic analyses of EPHESUS have found that the reduction in
hospitalization costs in the eplerenone group was not statistically
significant, and was not sufficient to offset the additional cost of
the drug (see Economic evidence section). On the current
evidence base, it thus seems likely that addition of eplerenone to
standard therapy would result in a net increase in healthcare
costs. However, the main economic analysis was conducted
using US Medicare costs, and the authors suggest that as
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Outcome Reference
Serum potassium
>5.5 mmol/L
Serum
potassium
≥6 mmol/L
Hospitalization
for hyperkalemia
Death due to
hyperkalemia
Death due to
hyperkalemia or any
sudden death
Death due to hyperkalemia
or any sudden death or any
unknown cause
NR Placebo 3.9%
Eplerenone 5.5%
P=0.002
Placebo 3
patients
Eplerenone 12
patientsa
Placebo 1 patient
Eplerenone 0
patientsa
NR NR Pitt et al. 2003b
Placebo 11.2%
Eplerenone 15.6%
P<0.001
NR NR Placebo 0.3%
Eplerenone 0%a
Placebo 6.1%
Eplerenone 4.9%
P=0.022
Placebo 6.6%
Eplerenone 5.3%
P=0.016
Pitt et al. 2004
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy included ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers (75%),
and coronary reperfusion therapy (45%).
aNo between-group comparison reported.
NR, not reported.
Table 9 | Effects of eplerenone on serum potassium [level 2 evidence, main analysis of the EPHESUS study (Pitt et al. 2003b) and a
post-hoc analysis (Pitt et al. 2004)]137
Medicare costs tend to be lower than US managed care costs
their analysis may have underestimated the potential savings in
hospital costs with eplerenone (Weintraub et al. 2005). Further
economic analyses using other unit costs and in other countries
are required to assess this possibility. 
Eplerenone has shown clear evidence of a survival benefit, and it
is possible that this could translate into a reduced loss of working
days and thus a reduction in indirect cost. Such a reduction in
indirect cost might offset more of the eplerenone cost, although
there is as yet no evidence that this is the case. The net gain in
life-years with eplerenone was quite small, averaging about 0.1
life-years gained per patient (see Economic evidence section
above), which may suggest that any corresponding gain in
indirect costs might also be small. As heart failure is primarily a
disease of elderly people, a substantial proportion of patients may
no longer be economically active, and this would also tend to
suggest that any gain in indirect costs may be modest.
The evidence base at present shows quite clearly that the
addition of eplerenone to standard therapy is both more effective
and more costly than standard therapy alone. Cost effectiveness
for the addition of eplerenone in the US was estimated at
$US10 402–21 876 per life-year gained or $US15 330–32 405 per
QALY (Weintraub et al. 2005). The authors of this US economic
analysis argued that the cost-effectiveness ratios for eplerenone
compared favorably with those for other interventions in
cardiology (Weintraub et al. 2005). For example, they cited
previous cost-effectiveness estimates for captopril therapy versus
no captopril in post-MI patients ($US3700–10 400 per QALY,
Tsevat et al. 1995), and implantable cardiac defibrillators versus
amiodarone in survivors of cardiac arrest ($US37 300 per QALY,
Owens et al. 1997). The authors also considered that the cost
effectiveness of eplerenone was below a “threshold” for
acceptable cost effectiveness of $US50 000 per life-year gained
(Weintraub et al. 2005). Whether the additional benefits of
eplerenone justify the additional costs is a matter for decision
makers in individual healthcare systems.
Patient group/population
The EPHESUS patient population consisted of men and women
with heart failure and left ventricular systolic dysfunction 3–14
days following an acute MI (Pitt et al. 2003b). Inclusion and
exclusion criteria are summarized in Table 11. The mean age was
64 years and 90% of patients were white. The mean left
ventricular ejection fraction was 33% (Pitt et al. 2003b). As the
EPHESUS study provides the entire current evidence base for
eplerenone in post-MI heart failure, this is the only population to
which the results can be confidently applied. However, it is likely
that a very high percentage of patients with post-MI heart failure
would meet the selection criteria used in EPHESUS (B. Pitt,
personal communication). A substudy of 134 eplerenone-treated
patients in EPHESUS found that the pharmacokinetic behavior of
eplerenone in this population was similar to that in healthy
volunteers of similar age (Reid et al. 2003). 
EPHESUS included several subgroup analyses (Table 11). In
general, the beneficial effects of eplerenone on both primary
endpoints (all-cause mortality and combined cardiovascular
hospitalization/mortality) were similar in the subgroups and in the
main analysis (Pitt et al. 2003b). However, it should be noted that
EPHESUS was not powered to detect differences among
subgroups.
A retrospective analysis of the 4007 EPHESUS patients with
hypertension found that addition of eplerenone reduced all-cause
mortality (P=0.001) and combined cardiovascular
mortality/hospitalization (P=0.002) compared with standard
therapy alone (Pitt et al. 2003a).
A further retrospective analysis studied the 1483 patients with
diabetes and signs of heart failure in EPHESUS. In this subgroup,
the eplerenone-treated patients had lower all-cause mortality,
combined cardiovascular mortality/hospitalization, and
cardiovascular mortality compared with the patients receiving
standard therapy alone. However, the 95% confidence intervals
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Country Outcome Reference
Difference in mean costs per patient over 16-month mean follow-up, eplerenone minus placebo
Rehospitalization Eplerenone Other medication Outpatient procedures ER visits Total
USA –$US207 (95% CI
–887, 504)
$US1513  $US55 (95% CI 
–67, 173)
$US34 (95% CI
–34, 105)
–$US4 (95% CI
–10, 1)
$US1391 (95% CI
656, 2165)
Weintraub et
al. 2005
The Netherlands –€162 (95% CI
–472, 136)
NR €3.5 (95% CI
–35, 42)
€44 (95% CI 
–63, 154)
–€3.9 (95% CI
–8.8, 1.8)
NR Zhang &
Weintraub
2004
Patients were randomized to receive standard therapy plus either placebo (n=3313) or eplerenone (25 mg/day for 4 weeks, then titrating up to a target dose of 50 mg/day, n=3319) in a double-
blind trial, with a mean of 16 months of follow-up. Standard therapy could include ACE inhibitors or angiotensin II receptor antagonists (87%), diuretics (60%), aspirin (88%), beta blockers
(75%), and coronary reperfusion therapy (45%).
CI, confidence interval; ER, emergency room; NR, not reported.
Table 10 | Estimated costs with eplerenone (level 2 evidence, economic analyses of the EPHESUS study with unit costs for two
countries)for the risk ratio included 1 for all-cause and cardiovascular
mortality, indicating that statistical significance was not achieved
for these endpoints (O’Keefe et al. 2004). 
Patients with low baseline creatinine clearance (<50 mL/min) were
at elevated risk for eplerenone-associated hyperkalemia in
EPHESUS. In this subgroup, the incidence of serious
hyperkalemia (serum potassium ≥6 mmol/L) was 10.1% in
eplerenone-treated patients compared with 5.9% in the patients
receiving standard therapy alone (P=0.006) (Pitt et al. 2003b). This
suggests that serum potassium needs to be monitored with
special care in patients with low creatinine clearance.
A separate open-label study in 32 patients with varying degrees
of renal impairment and 32 matched healthy controls found that
the pharmacokinetics of eplerenone (area under the curve, total
clearance, and maximum plasma concentration) following single
(100 mg) or multiple dosing (100 mg/day for 5 days) were not
significantly affected by renal impairment (Ravis et al. 2005). This
study concluded that no adjustment of the eplerenone dose is
necessary in patients with renal impairment, although dose
adjustment may be required depending on the potential for
clinically relevant hyperkalemia (Ravis et al. 2005).
Dosage, administration, and formulations
Eplerenone (Inspra®) is indicated to improve survival of stable
patients with left ventricular systolic dysfunction (ejection fraction
≤40%) and clinical evidence of congestive heart failure after an
acute MI (Anon. 2005). Inspra® is supplied as film-coated tablets
containing 25 or 50 mg eplerenone.
Eplerenone is contraindicated in patients with serum potassium
higher than 5.5 mmol/L at the beginning of treatment, and in
patients with creatinine clearance ≤30 mL/min. Eplerenone is
also contraindicated for concomitant use with potent inhibitors of
cytochrome P450 3A4, including ketoconazole, itraconazole,
nefazodone, troleandomycin, clarithromycin, ritonavir, and
nelfinavir (Anon. 2005).
The recommended eplerenone dosage in post-MI heart failure 
is 50 mg once daily. The starting dose should be 25 mg 
once daily, titrated to the target dose of 50 mg once daily 
as tolerated by the patient and preferably within 4 weeks
(Anon. 2005). 
Serum potassium should be measured before beginning
eplerenone treatment, within the first week and at 1 month after
beginning treatment or after each dose adjustment, and
periodically thereafter. The eplerenone dose should be adjusted
according to the serum potassium level as follows: 
• serum potassium level <5 mmol/L: increase eplerenone dose
from 25 mg every other day to 25 mg once daily, or from
25 mg once daily to 50 mg once daily
• serum potassium level 5–5.4 mmol/L: no eplerenone dose
adjustment
Eplerenone | place in therapy review
© 2005 Core Medical Publishing Limited 138
Inclusion criteria Acute myocardial infarction as documented by standard criteria
Left ventricular dysfunction as documented by a left ventricular ejection fraction of ≤40% on echocardiography, radionuclide
angiography, or angiography of the left ventricle after the index acute myocardial infarction but before randomization
Heart failure as documented by the presence of pulmonary rales, pulmonary venous congestion shown on chest radiography, or
presence of a third heart sound 
In patients with diabetes, the third criterion (symptoms of heart failure) was not necessary as patients with diabetes are considered to
have a risk of cardiovascular events similar to that of patients without diabetes but with symptoms of heart failure
Exclusion criteria Taking potassium-sparing diuretics
Serum creatinine concentration >2.5 mg/dL (220 µmol/L)
Serum potassium >5 mmol/L
Subgroups analyzed Sex
Age (dichotomized at <65 years)
Pulse pressure
Serum potassium concentration <4 mmol/L
Serum creatinine concentration <1.1 mg/L
Ejection fraction <35%
Use of percutaneous transluminal coronary revascularization and cardiovascular medication (angiotensin-converting enzyme inhibitors,
angiotensin II receptor antagonists, beta blockers, aspirin, diuretics, lipid-lowering agents)
Diabetes
Hypertension
Table 11 | Patient population in the EPHESUS study (adapted from Pitt et al. 2003b)
 139
• serum potassium level 5.5–5.9 mmol/L: decrease eplerenone
dose from 50 mg once daily to 25 mg once daily, or from 25 mg
once daily to 25 mg every other day; if the dose is already
down to 25 mg every other day, eplerenone should be withheld
• serum potassium level ≥6 mmol/L: withhold eplerenone.
Eplerenone may be restarted at a dose of 25 mg every other day
when serum potassium levels have fallen to below 5.5 mmol/L
(Anon. 2005).
No adjustment of the starting dose is recommended for elderly
patients or patients with mild-to-moderate hepatic impairment. 
Place in therapy
The evidence summary table at the beginning of this article
summarizes the available clinical and economic evidence on
eplerenone in patients with post-MI heart failure. Almost all the
evidence (except for one small pharmacokinetic study) is
derived from EPHESUS, a large double-blind multicenter RCT
conducted in over 6000 patients. The main efficacy outcomes in
EPHESUS were patient-oriented, measuring mortality and/or
hospitalization. The study also collected data on other patient-
oriented outcomes such as health status and functional
capacity, but as yet this information does not appear to have
been published. The main disease-oriented evidence related to
the incidence of hyperkalemia, a well-known and potentially
serious side effect of drugs that suppress the renin-angiotensin-
aldosterone system. 
As EPHESUS compared eplerenone plus standard therapy with
standard therapy alone, the results are of clear relevance to
current practice. Patients were treated with ACE inhibitors or
angiotensin II receptor antagonists (87% of patients), beta
blockers (75%), aspirin (88%), and diuretics (60%). In addition,
45% of patients received reperfusion therapy or revascularization
(Pitt et al. 2003b). This suggests that the survival benefit produced
by addition of eplerenone to standard therapy was a genuine
improvement over what can be achieved by current best practice,
and cannot be attributed to undertreatment in the control group.
However, clinical trials are likely to have a higher degree of patient
monitoring than is possible in routine practice, and are conducted
in defined and selected patient populations. Whether the results
can be generalized to populations of heart failure patients other
than the population selected for EPHESUS requires further
evidence. However, as the EPHESUS population is considered
likely to represent a high proportion of patients with post-MI heart
failure (B. Pitt, personal communication), the results are likely to
be applicable to many, perhaps most, patients in clinical practice.
Clear evidence shows that addition of eplerenone to standard
therapy improves all-cause mortality and combined
cardiovascular mortality/hospitalization compared with standard
therapy alone. There is also evidence of benefit on secondary
endpoints including cardiovascular mortality, risk of sudden
cardiac death, and combined all-cause mortality/hospitalization.
There was no significant improvement on the risk of
cardiovascular hospitalization, though EPHESUS was not
powered on this endpoint. The trial also provided evidence that
eplerenone had an incidence of hormonal side effects that was no
greater than placebo. This contrasts with the 10% incidence of
hormonal side effects observed with spironolactone in the RALES
study (Pitt et al. 1999), indicating that eplerenone may be better
tolerated in this regard than spironolactone.
Limited evidence from a post-hoc analysis indicated that
eplerenone treatment could be associated with a shorter length of
stay in patients hospitalized for heart failure. Similarly, limited
evidence from a substudy found that although eplerenone was
associated with higher mean utility score (indicating better health-
related quality of life) than standard therapy alone at 12 months,
the difference did not reach statistical significance.
There is evidence that eplerenone treatment is associated with a
higher risk of hyperkalemia than standard therapy alone,
especially in patients with low creatinine clearance. In the
EPHESUS study, where patients with high serum creatinine
and/or potassium at baseline were excluded and where serum
potassium was regularly monitored throughout treatment,
evidence from a post-hoc analysis indicated that the
hyperkalemia was nonfatal and manageable. However, this
emphasizes the need for monitoring of serum potassium and
dose adjustment as necessary during use of eplerenone in routine
practice.
Economic analyses showed that the addition of eplerenone was
more costly than standard treatment alone, as well as more
effective. Although small and nonsignificant reductions in hospital
costs were observed, they were not sufficient to offset the
additional cost of eplerenone. The cost-effectiveness ratio in the
EPHESUS population was estimated at $US10 402–$US21 876
per life-year gained (depending on the method used to estimate
life-years). The study authors considered that this compares
favorably with other cardiology interventions such as ACE
inhibitor use after MI. It will be for individual decision makers to
assess whether this represents acceptable value in their particular
healthcare systems and institutions.
EPHESUS demonstrated clinical benefit with eplerenone in a
large population (over 6000) of patients with post-MI heart failure.
The population enrolled in EPHESUS is considered likely to
represent a high proportion of patients with post-MI heart failure.
It may be that eplerenone could also be beneficial in other
populations, such as the patients with severe heart failure who
benefited from spironolactone treatment in the RALES study, but
there is as yet no evidence on this issue. It has been
recommended that formularies should include both drugs, with
eplerenone used in patients who resemble the EPHESUS
population and spironolactone used in patients who resemble
the RALES population (Pitt 2003; Barnes & Howard 2005).
Patients receiving spironolactone who develop intolerable
hormonal side effects could reasonably be given a trial of
eplerenone, in the light of its low incidence of such side effects
(Pitt 2003; Barnes & Howard 2005). However, at US average
wholesale prices generic spironolactone is considerably cheaper
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month) (Barnes & Howard 2005). Other authorities have
suggested that spironolactone could be tried first (Jessup 2003).
Evidence from trials directly comparing eplerenone and
spironolactone is needed to fully assess the optimum place in
therapy for the two drugs, but at present no comparative data are
available.
In summary, the current evidence base indicates that
eplerenone improves survival and reduces cardiovascular
hospitalization/mortality, compared with standard treatment
alone, in patients with heart failure as a complication after acute
MI. The incidence of hormonal side effects is no greater than
with placebo. Eplerenone is associated with an elevated risk of
hyperkalemia that necessitates regular monitoring of serum
potassium and dose adjustment as required. Eplerenone is both
more effective and more costly than standard treatment alone,
and decision makers will need to assess whether this represents
added therapeutic value in their own situations.
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